| 154.84 6.63 (4.47%) | 06-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 181.03  |
1-year : | 211.45 |
| Resists | First : | 155 |
Second : | 181.03 |
| Pivot price | 119.06 |
|||
| Supports | First : | 121.01 |
Second : | 100 |
| MAs | MA(5) : | 137.55 |
MA(20) : | 117.1 |
| MA(100) : | 117.15 |
MA(250) : | 88.19 |
|
| MACD | MACD : | 6.6 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 95.5 |
D(3) : | 94.5 |
| RSI | RSI(14): 75.4 |
|||
| 52-week | High : | 155 | Low : | 21.54 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PVLA ] has closed It is unclear right now based on current values. 100.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 155.02 - 155.56 | 155.56 - 156.05 |
| Low: | 146.41 - 147.09 | 147.09 - 147.71 |
| Close: | 153.73 - 154.71 | 154.71 - 155.6 |
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Mon, 29 Jun 2026
Palvella submits first module of NDA for rare skin disease therapy - Investing.com UK
Mon, 29 Jun 2026
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell Microcap Index - marketscreener.com
Mon, 29 Jun 2026
Palvella submits FDA NDA for QTORIN gel - grafa.com
Mon, 29 Jun 2026
Palvella Therapeutics Submits First Module of Rolling New - GlobeNewswire
Mon, 29 Jun 2026
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Fri, 26 Jun 2026
Price to earnings forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 96.3 (%) |
| Shares Short | 2,080 (K) |
| Shares Short P.Month | 2,150 (K) |
| EPS | -4.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.22 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -34.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -37.14 |
| PEG Ratio | 0 |
| Price to Book value | 9.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -76.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|